We strive to make unique discoveries
“Symphogen has been successful in recruiting very passionate people.”
Symphogen is the Antibody Center of Excellence in the Servier Group. We apply our highly efficient antibody platform and capabilities in the discovery and early development of differentiated antibody therapeutics, either as combination or mono therapies.
We were founded in 2000 and became part of the Servier Group in June 2020 to support Servier’s commitment to improve patient’s health and the R&D strategy within oncology and immune oncology. Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and 4.9 billion euros consolidated sales revenue in 2022, Servier employs >20,000 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in research and development every year.
To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient’s voice at the heart of its activities, from research to support beyond the pill.
A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neurosciences, and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.
Please see servier.com for more information.